# Evaluating the Efficacy of Dual Layer Amniotic Membrane (Artacent®)

> **NCT04457752** · PHASE4 · UNKNOWN · sponsor: **SerenaGroup, Inc.** · enrollment: 124 (estimated)

## Conditions studied

- Chronic Diabetic Foot Ulcers

## Interventions

- **BIOLOGICAL:** Dual Layer Amniotic Membrane (DLAM). Artacent®

## Key facts

- **NCT ID:** NCT04457752
- **Lead sponsor:** SerenaGroup, Inc.
- **Sponsor class:** NETWORK
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-09-01
- **Primary completion:** 2022-03-01
- **Final completion:** 2023-03-31
- **Target enrollment:** 124 (ESTIMATED)
- **Last updated:** 2022-11-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04457752

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04457752, "Evaluating the Efficacy of Dual Layer Amniotic Membrane (Artacent®)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04457752. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*